Deborah Dunsire aims for 10 European Vyepti launches this year
A series of Vyepti launches is slated to begin within the next half year, with Lundbeck preparing the migraine drug for as many as 10 European countries this year, according to CEO Deborah Dunsire.
by ANDREAS LØNSTRUP, translated by daniel pedersen
In January, Lundbeck received the much anticipated European approval of migraine drug Vyepti, and the pharmaceutical company has great expectations for the treatment.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck's Northera took massive dive in 2021
For subscribers
